Compare NUTX & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUTX | TNGX |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | 944 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.5B |
| IPO Year | 2009 | 2020 |
| Metric | NUTX | TNGX |
|---|---|---|
| Price | $94.00 | $18.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $252.50 | $18.75 |
| AVG Volume (30 Days) | 162.0K | ★ 3.3M |
| Earning Date | 06-15-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.93 | ★ 26.89 |
| EPS | ★ 10.48 | N/A |
| Revenue | ★ $875,257,000.00 | $62,384,000.00 |
| Revenue This Year | $18.71 | N/A |
| Revenue Next Year | $2.79 | $13.81 |
| P/E Ratio | $9.25 | ★ N/A |
| Revenue Growth | ★ 82.36 | 48.29 |
| 52 Week Low | $45.88 | $1.04 |
| 52 Week High | $193.07 | $18.50 |
| Indicator | NUTX | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 76.23 |
| Support Level | $81.70 | $5.98 |
| Resistance Level | $110.29 | N/A |
| Average True Range (ATR) | 8.37 | 1.28 |
| MACD | 0.33 | 0.43 |
| Stochastic Oscillator | 26.41 | 94.06 |
Nutex Health Inc is healthcare services and operations company with 20 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospital division implements and operates healthcare models, including micro-hospitals, specialty hospitals and hospital outpatient departments (HOPDs). The population health management division owns and operates provider networks such as independent physician associations (IPAs) and offers a cloud-based proprietary technology platform to IPAs that aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.